Clal Biotechnology Industries Ltd - Asset Resilience Ratio

Latest as of December 2024: 1.56%

Clal Biotechnology Industries Ltd (CBI) has an Asset Resilience Ratio of 1.56% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Clal Biotechnology Industries Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

ILA1.06 Million

≈ $2.84K USD Cash + Short-term Investments

Total Assets

ILA67.69 Million

≈ $181.47K USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2007–2024)

This chart shows how Clal Biotechnology Industries Ltd's Asset Resilience Ratio has changed over time. See CBI book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Clal Biotechnology Industries Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Clal Biotechnology Industries Ltd (CBI) market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	ILA0.00	0%
Short-term Investments	ILA1.06 Million	1.56%
Total Liquid Assets	ILA1.06 Million	1.56%

Asset Resilience Insights

Limited Liquidity: Clal Biotechnology Industries Ltd maintains only 1.56% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Clal Biotechnology Industries Ltd Industry Peers by Asset Resilience Ratio

Compare Clal Biotechnology Industries Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Sagimet Biosciences Inc. Series A Common Stock NASDAQ:SGMT	Biotechnology	63.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	43.36%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	2.34%
Bio-Thera Solutions Ltd SHG:688177	Biotechnology	4.09%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Gubra A/S CO:GUBRA	Biotechnology	79.61%

Annual Asset Resilience Ratio for Clal Biotechnology Industries Ltd (2007–2024)

The table below shows the annual Asset Resilience Ratio data for Clal Biotechnology Industries Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	1.56%	ILA1.06 Million ≈ $2.84K	ILA67.69 Million ≈ $181.47K	-3.25pp
2023-12-31	4.82%	ILA7.63 Million ≈ $20.45K	ILA158.39 Million ≈ $424.63K	+1.84pp
2022-12-31	2.98%	ILA5.44 Million ≈ $14.59K	ILA182.69 Million ≈ $489.79K	-16.29pp
2020-12-31	19.27%	ILA118.34 Million ≈ $317.26K	ILA614.03 Million ≈ $1.65 Million	+6.80pp
2019-12-31	12.48%	ILA76.98 Million ≈ $206.38K	ILA616.97 Million ≈ $1.65 Million	+6.24pp
2018-12-31	6.24%	ILA63.40 Million ≈ $169.98K	ILA1.02 Billion ≈ $2.72 Million	+6.16pp
2017-12-31	0.08%	ILA830.00K ≈ $2.23K	ILA1.03 Billion ≈ $2.77 Million	-0.40pp
2016-12-31	0.48%	ILA5.39 Million ≈ $14.46K	ILA1.12 Billion ≈ $3.00 Million	-2.05pp
2015-12-31	2.53%	ILA38.81 Million ≈ $104.04K	ILA1.53 Billion ≈ $4.11 Million	-10.97pp
2014-12-31	13.51%	ILA227.94 Million ≈ $611.09K	ILA1.69 Billion ≈ $4.52 Million	+9.04pp
2013-12-31	4.47%	ILA85.81 Million ≈ $230.05K	ILA1.92 Billion ≈ $5.15 Million	-1.25pp
2012-12-31	5.71%	ILA99.93 Million ≈ $267.92K	ILA1.75 Billion ≈ $4.69 Million	-8.52pp
2011-12-31	14.23%	ILA177.97 Million ≈ $477.12K	ILA1.25 Billion ≈ $3.35 Million	+5.54pp
2010-12-31	8.69%	ILA118.56 Million ≈ $317.86K	ILA1.36 Billion ≈ $3.66 Million	-3.09pp
2009-12-31	11.78%	ILA110.34 Million ≈ $295.83K	ILA936.32 Million ≈ $2.51 Million	+5.64pp
2008-12-31	6.15%	ILA26.18 Million ≈ $70.17K	ILA425.92 Million ≈ $1.14 Million	+5.85pp
2007-12-31	0.29%	ILA1.23 Million ≈ $3.30K	ILA420.47 Million ≈ $1.13 Million	--

pp = percentage points

About Clal Biotechnology Industries Ltd

TA:CBI Israel Biotechnology

Market Cap

$12.61 Million

ILA4.71 Billion ILA

Market Cap Rank

#26439 Global

#380 in Israel

Share Price

ILA30.00

Change (1 day)

+0.33%

52-Week Range

ILA27.30 - ILA42.50

All Time High

ILA380.64